U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. Draft Guidance for Industry: Action Levels for Lead in Juice
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

Draft Guidance for Industry: Action Levels for Lead in Juice April 2022

Download the Draft Guidance Document Read the Federal Register Notice
Draft

Not for implementation. Contains non-binding recommendations.

Docket Number:
FDA-2019-D-5609
Issued by:
Guidance Issuing Office
Human Foods Program

FDA is committed to reducing lead in food to the extent feasible. FDA’s Closer to Zero action plan is a science-based, iterative approach to decreasing toxic elements (such as lead) in foods over time, including by setting action levels. This guidance provides information to industry on the action levels for lead in juice.  The action levels for lead in juice in this document would, if finalized, replace the current level of 50 parts per billion (ppb) described in the Guidance for Industry: Juice Hazard Analysis Critical Control Point Hazards and Controls Guidance (Juice HACCP Guidance), First Edition (Ref. 1).  FDA considers the action levels described in this guidance to be achievable by industry (or you) when measures are taken to minimize the presence of lead. 

The contents of this document do not have the force and effect of law and are not meant to bind the public in any way, unless specifically incorporated into a contract. This document is intended only to provide clarity to the public regarding existing requirements under the law.  FDA guidance documents, including this guidance, should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited.  The use of the word should in FDA guidance means that something is suggested or recommended, but not required.

Download the Draft Guidance

Related Information

Submit Comments

Submit Comments Online

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2019-D-5609.

Back to Top